Navigation Links
Poniard Pharmaceuticals Reschedules Fourth Quarter and Fiscal 2008 Results Conference Call for Monday, March 16
Date:3/10/2009

SOUTH SAN FRANCISCO, Calif., March 10 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced that it has rescheduled its earnings call regarding its fourth quarter and year-end 2008 financial results, which was previously scheduled to be held on Thursday, March 12, 2009 at 8:30 a.m. Eastern Time, in order to complete its financial statement close and audit process. The Company will hold its conference call, issue a press release for the fourth quarter and year-ended December 31, 2008 and file its Annual Report on Form 10-K after market close on Monday, March 16, 2009.

Jerry McMahon, Ph.D., chairman and chief executive officer, Ronald A. Martell, president and chief operating officer, Greg Weaver, chief financial officer, and Robert De Jager, M.D., FACP, chief medical officer, will host the rescheduled call beginning at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) on Monday, March 16.

To participate in the live call by telephone, please dial 877-719-9791 from the U.S. or 719-325-4811 for international callers. In addition, the live conference call is being webcast and can be accessed on the "Events" page of the "News & Events" section of the Company's website at http://www.poniard.com. A replay of the webcast will be available on the Company's website for 10 days.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum chemotherapy. To date, clinical studies suggest that picoplatin ha
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Poniard Pharmaceuticals to Host Fourth Quarter and Year-End 2008 Financial Results Conference Call on March 12
2. Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer
3. Poniard Pharmaceuticals to Present at the BIO CEO & Investor Conference
4. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers
6. Poniard Pharmaceuticals Announces Commercial Supply Agreement for Picoplatin
7. Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results Conference Call on October 30
8. Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
9. Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer
10. Poniard Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
11. Poniard Pharmaceuticals Announces Upcoming Conference Participation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Burkina Faso (PRWEB) July 10, 2014 ... Faso, today have access to an additional family ... increase access to contraception at all levels of ... a lower-dose formulation of a widely used contraceptive—Pfizer’s ... system. , Burkina Faso is the first of ...
(Date:7/10/2014)... Terascala, the industry leader in HPC ... former vice president of product management for Flexera Software, ... marketing. Terascala’s software when combined with leading compute and ... performance and most reliable solutions for processing big data. ... expansion and broaden its product portfolio. His leadership in ...
(Date:7/10/2014)... QC (PRWEB) July 10, 2014 EvoDerma ... and convenience. This rejuvenating device now comes with a second ... develops over time. , The new cup is thinner on ... design works to target rough, thin and uneven surfaces on ... firm cup for a stimulating treatment on areas such as ...
(Date:7/10/2014)...  Kainos Capital, a firm specializing in acquiring and ... has acquired the Slim-Fast brand from Unilever. Unilever will ... the transaction were not disclosed. Slim-Fast is ... markets ready-to-drink shakes, powders, bars and snacks to retail ... in the United Kingdom and ...
Breaking Biology Technology:Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Terascala Expands Executive Team 2Terascala Expands Executive Team 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Kainos Capital Acquires Slim-Fast From Unilever 2
... SAN FRANCISCO, March 20, 2012 /PRNewswire/ -- ... focused on the development and commercialization of first-in-class ... that the first patient has been treated in ... patients with metastatic colorectal cancer who have become ...
... GARDEN CITY, England and BOSTON, Massachusetts, March 20, 2012 ... discovery company, announces that an operating company of Shire ... global specialty biopharmaceutical company, has exercised its exclusive option ... discovered by Heptares that is currently in preclinical development. ...
... Holdings, Inc. (OTCQB: ONVO) ("Organovo") today announced the ... At the final closing, the Company raised gross proceeds ... Units, at a price of $1.00 per Unit, to ... of common stock issued and outstanding. As ...
Cached Biology Technology:Jennerex Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594 in Combination with Irinotecan in Patients with Metastatic Colorectal Cancer 2Jennerex Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594 in Combination with Irinotecan in Patients with Metastatic Colorectal Cancer 3Jennerex Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594 in Combination with Irinotecan in Patients with Metastatic Colorectal Cancer 4Jennerex Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594 in Combination with Irinotecan in Patients with Metastatic Colorectal Cancer 5Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders 2Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders 3Organovo Announces Close of $15.2 Million Private Placement to Advance 3D Bioprinting for Medical Applications 2Organovo Announces Close of $15.2 Million Private Placement to Advance 3D Bioprinting for Medical Applications 3
(Date:7/10/2014)... 3, 2014 According to the ... (Swipe And Area), Material (Optical Prism, Pizeoelectric, Capacitive, and ... and Banking & Finance), and Geography - Global Trends ... the global Fingerprint Sensors Market is projected to cross ... of 16.8% from 2014 to 2020. Browse ...
(Date:7/10/2014)... York , July 7, 2014 ... Transparency Market Research "Electronic Access Control Systems Market Global ... - 2019," the global Electronic Access Control systems market ... is expected to grow at a CAGR of 12.6% ... of USD 31,187.8 million in 2019. Browse ...
(Date:7/10/2014)... NORTHFIELD, Ill. , July 9, 2014 /PRNewswire-USNewswire/ ... record (EHR), spurred in large part by meaningful ... way health care providers interact with laboratory information. ... well-versed in the field of clinical informatics in ... care. To address the educational needs ...
Breaking Biology News(10 mins):Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 2Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 3Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 4Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 5New Clinical Informatics Curriculum Prepares Future Pathologists 2New Clinical Informatics Curriculum Prepares Future Pathologists 3New Clinical Informatics Curriculum Prepares Future Pathologists 4
... (Santa Barbara, Calif.) A newly discovered species of monitor ... in the journal Zootaxa this week by a ... Sam Sweet, a professor in the department of Ecology, ... graduate student at Abo Akademi University in Turku, Finland, are ...
... live in the nicest possible house, ideally with regular ... School of Arts and Sciences and the New England ... improved housing using previously unknown social networking skills. ... models to uncover some surprising new tricks that could ...
... MD The Genetics Society of America is pleased ... for poster awards at the 51st Annual Drosophila Research ... selected for first, second and third place awards for ... This was the first time that undergraduate student research ...
Cached Biology News:New monitor lizard discovered in Indonesia 2Social networking helps hermit crabs find homes 2Social networking helps hermit crabs find homes 3Genetics Society of America announces award recipients at 51st Annual Drosophila Conference 2
Contact us for more information...
... System enables you to insert a transposable ... DNA by in vitro transposition. It uses ... into the DNA target. Target DNA may ... DNA, depending on your interests (6-8). If ...
... APAgene kits are designed to rapidly ... using our patented APA Technology. ... at an extraordinarily competitive price. All ... kit. The Locator Kit can be ...
... c-Jun N-terminal kinase (JNK) is one ... Firefly luciferase has been used as a ... function. Luciferase provides a 1000-fold increase in ... acetyltransferase (CAT) assay. Firefly luciferase catalyzes the ...
Biology Products: